4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates

MT Newswires43minutes ago

4DMT Extends Cash Runway To 2028 With $506M, Plans Phase 3 Trials For 4FRONT-1 & 4FRONT-2 In Wet AMD, Develops Early-Stage DME And CF, Explores Partnerships And Strategic Financing

Benzinga08:03 ET

Express News | 4D Molecular Therapeutics Inc: Cash Runway Extended Under Updated Operating Plan Expected to Fund Operations Into 2028

Reuters08:01 ET

Express News | 4D Molecular Therapeutics Inc: Primary Endpoint 52-Week Topline Data for Both 4Front-1 and 4Front-2 Expected in H2 2027

Reuters08:01 ET

Express News | 4D Molecular Therapeutics Inc - 4D-150 Well Tolerated With No Intraocular Inflammation Observed

Reuters08:01 ET

Express News | 4Dmt Announces Positive Interim Data From 4D-150 Spectra Clinical Trial in Dme and Alignment With FDA on Registrational Path

Reuters08:00 ET